NCT06585514View on ClinicalTrials.gov

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)

Interventions

DRUG

CD19 CAR-T cells

Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.

Trial Locations (1)

102206

RECRUITING

Beijing GoBroad Hospital, Beijing

All Listed Sponsors

lead

Beijing GoBroad Hospital

OTHER